Staphylococcus Aureus

If you have ongoing vaginal symptoms that don't fit bacterial vaginosis, yeast, or an STI, you may be looking past one of the more common culprits in your microbiome. Staphylococcus aureus is a bacterium most people associate with skin or nasal infections, but it also colonizes the vagina, where it can sit quietly or fuel an inflamed, irritated state called aerobic vaginitis.

This swab tells you whether S. aureus (Staphylococcus aureus) is present in your vaginal flora, which matters for women with unexplained discharge, anyone considering pregnancy, and women already in pregnancy whose newborns can pick up the same bacteria during delivery.

What This Test Is Looking For

S. aureus is a gram-positive bacterium, meaning it has a thick outer wall that stains a particular color under a microscope. It lives on skin and mucous membranes, and in some women it takes up residence in the vaginal lining without causing symptoms. In others, the same bacterium drives inflammation, releases toxins, and crowds out the protective Lactobacillus species that normally keep the vagina at a healthy, slightly acidic pH.

The reason a single bacterium can behave so differently comes down to the specific strain. Vaginal S. aureus isolates studied in women with aerobic vaginitis frequently carry virulence genes for hemolysins, enterotoxins, and toxic shock syndrome toxin-1, and most form biofilms (sticky bacterial communities that resist immune attack and antibiotics). A swab that comes back positive is the first piece of information; the strain and its resistance profile determine what that finding actually means for you.

Why You Might Be Carrying It

S. aureus is more common in the vagina than most people realize. In a study of 1,472 women in labor in Uganda, 8.2% carried S. aureus vaginally, and 5.8% carried the methicillin-resistant version (MRSA), a strain that doesn't respond to the older penicillin-family antibiotics. In a separate study of 1,139 women near term, 5.9% tested positive within a month of delivery. Among women showing up to a gynecology clinic with abnormal vaginal discharge in Uganda, S. aureus was the single most common bacterium isolated, found in 48.6% of positive cultures. Older US studies have reported vaginal carriage closer to 9% to 10% in healthy women, and individual studies have ranged anywhere from 5% to 26% depending on the population sampled.

In women with aerobic vaginitis specifically, S. aureus shows up frequently. Among Ethiopian pregnant women with aerobic vaginitis, S. aureus made up 29.5% of bacterial isolates. A Chinese study characterized vaginal S. aureus isolates from 38 women with aerobic vaginitis, but it selected S. aureus-positive cases for the analysis, so it describes what those isolates look like rather than how often S. aureus appears in aerobic vaginitis overall.

Aerobic Vaginitis and Vaginal Symptoms

Aerobic vaginitis is the condition most directly tied to vaginal S. aureus. It looks similar to bacterial vaginosis (loss of Lactobacillus, higher pH, abnormal discharge) but is driven by aerobic bacteria like S. aureus rather than the anaerobic mix seen in bacterial vaginosis. The inflammation is more pronounced, and the same bacteria can produce toxins that damage immune cells and irritate the vaginal lining. This distinction also matters for treatment: metronidazole, the standard option for bacterial vaginosis, is not appropriate for aerobic vaginitis because it does not cover aerobic organisms like S. aureus.

In the Chinese series of women with aerobic vaginitis, S. aureus isolates frequently carried virulence and efflux pump genes (cellular machinery that pumps antibiotics back out of the bacterium), and most strains formed strong biofilms. This combination helps explain why some women have persistent or recurrent symptoms even after antibiotic treatment: the bacteria are physically protected and chemically defended.

Pregnancy and Newborn Risk

The most established reason to know your vaginal S. aureus status is what it means for a newborn passing through the birth canal. In the study of 1,139 women near term, newborns of S. aureus carriers were colonized with the same bacterium 31.3% of the time, compared with 2.7% of newborns whose mothers were not carriers, roughly a twelvefold higher rate. In a separate study, maternal colonization during pregnancy or at delivery was tied to higher odds of infant staphylococcal colonization in the first weeks of life, with odds ratios in the range of 2 to 5 depending on timing.

Most colonized newborns don't develop serious illness. But colonization is the entry point for skin and soft tissue infections, and in rare cases sepsis; one prospective study found maternal MRSA colonization was tied to a roughly sevenfold higher odds of neonatal skin and soft tissue infection. If you are pregnant or planning a pregnancy, knowing your carrier status gives your delivery team information they can act on, particularly if the strain is methicillin-resistant or carries virulence genes. It is worth noting that ACOG does not currently recommend universal prenatal screening for MRSA colonization, citing insufficient data; this test is best considered in the context of specific clinical questions rather than as a routine screen for everyone.

Resistance Patterns Matter More Than Presence Alone

Vaginal S. aureus isolates can be resistant to the antibiotics most commonly used for vaginal infections, and resistance rates vary widely by region. In Ugandan women in labor, 55% of vaginal S. aureus isolates were MRSA. In Ethiopian women with aerobic vaginitis, all staphylococci tested were resistant to penicillin. Chinese aerobic vaginitis isolates showed 68.4% penicillin resistance, with better susceptibility to ciprofloxacin. These figures come largely from sub-Saharan Africa and parts of Asia and are substantially higher than what is typically seen in high-income countries: a global meta-analysis found pooled maternal MRSA prevalence of about 3.2%, with rates near 9% in Africa versus under 1% in Europe.

This is why a positive result on its own is not enough to guide treatment. The lab report typically pairs the identification with a susceptibility panel showing which antibiotics will actually work against your specific isolate. Treating empirically without that information can drive resistance and leave the underlying infection unresolved.

Why This Test Is Not a Replacement for Standard Vaginitis Workup

S. aureus vaginal culture is a complementary test, not a substitute for the panels most clinicians run first. If you have symptoms, you still need to know whether bacterial vaginosis, Candida (yeast), Trichomonas, chlamydia, or gonorrhea is in the picture, because these are far more common causes of abnormal discharge. In one study of women with vaginal symptoms, 93.4% of those with a sexually transmitted infection also had bacterial vaginosis or yeast, so assuming one positive result rules out another is a mistake.

A reasonable approach is to think of S. aureus testing as the next layer when standard panels don't explain your symptoms, when aerobic vaginitis is suspected, or when you are pregnant and want a complete picture of what your newborn could be exposed to.

One-Time Reading vs Tracking

S. aureus vaginal carriage can be transient. A study tracking menstruating women over time found that only about 35% of vaginally colonized women were persistent carriers, while the rest were intermittent or transient; nasal carriage tends to be more persistent. A single positive or negative result captures only that moment. If you tested positive and were treated, a follow-up swab roughly 3 to 6 weeks after finishing antibiotics confirms whether the bacterium actually cleared, especially given how often resistance and biofilms cause treatment to fall short.

For women planning pregnancy or already pregnant, testing again in the third trimester gives the most relevant snapshot for delivery planning. For ongoing symptoms, retesting alongside a full vaginitis panel is more informative than retesting in isolation, because the microbiome shifts and a new dominant organism may emerge.

When a Result Can Mislead You

A few things can distort what a single swab tells you:

• Recent antibiotic use: if you've been on antibiotics in the previous weeks, S. aureus may be temporarily suppressed even if it would otherwise be present, producing a falsely negative result.
• Menstrual cycle timing: vaginal microbial communities shift across the menstrual cycle, so a swab taken during menses may capture a different snapshot than one taken mid-cycle.
• Sample collection technique: swabbing too superficially or contaminating the swab with skin flora can change what the lab finds. Self-collection has been validated for some vaginal tests like group B strep and STI screening, but specific validation data for S. aureus self-collection is limited, so following the collection instructions carefully matters.
• Probiotic or vaginal product use: intravaginal probiotics, douches, or topical antimicrobials in the days before the test can temporarily shift the microbiome and obscure what is normally there.

What to Do With an Unexpected Result

If your swab comes back positive and you have symptoms, the next step is reviewing the susceptibility panel with a clinician and matching treatment to what the bacterium is actually sensitive to. Empirical treatment with a guessed antibiotic is the most common reason these infections recur.

If you are pregnant and positive, sharing the result with your obstetric team lets them plan around it, particularly if MRSA is identified. If you are positive but asymptomatic and not pregnant, the case for treatment is weaker, since carriage without symptoms is common and treatment carries its own costs (resistance, microbiome disruption). A follow-up swab in a few months, combined with attention to any new symptoms, is reasonable.

If your swab is negative but symptoms persist, do not assume the vagina has been cleared. Run a broader panel covering bacterial vaginosis, yeast, Trichomonas, chlamydia, and gonorrhea. A negative S. aureus result rules out S. aureus, not vaginitis in general.